➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Moodys
Colorcon
Johnson and Johnson
Dow

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 10,040,867

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,040,867
Title:Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
Abstract: It has been established that cancer cells with oncogenic mutants in the small GTPase K-Ras are susceptible to antibodies that bind intracellular guanosine, but delivery of antibodies into cells can be challenging. A subset of lupus autoantibodies is associated with anti-guanosine activity, and is capable of cellular penetration. These antibodies have potential as therapeutic agents targeted towards K-Ras associated malignancies.
Inventor(s): Hansen; James E. (Guilford, CT), Weisbart; Richard H. (Los Angeles, CA), Young; Melissa (New Haven, CT), Noble; Philip W. (New Haven, CT)
Assignee: Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC)
Application Number:15/123,195
Patent Claims:see list of patent claims

Details for Patent 10,040,867

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC) 2034-03-04 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC) 2034-03-04 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC) 2034-03-04 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC) 2034-03-04 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial Yale University (New Haven, CT) The United States of America, as Represented by The Department of Veterans Affairs (Washington, DC) 2034-03-04 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
McKinsey
Express Scripts
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.